

# Steven P Treon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/666718/publications.pdf>

Version: 2024-02-01

333  
papers

19,630  
citations

11651

70  
h-index

12946

131  
g-index

336  
all docs

336  
docs citations

336  
times ranked

9388  
citing authors

#	ARTICLE	IF	CITATIONS
1	MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2012, 367, 826-833.	27.0	1,142
2	Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. <i>Blood</i> , 2001, 98, 210-216.	1.4	869
3	Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 110-115.	2.2	841
4	Ibrutinib in Previously Treated Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2015, 372, 1430-1440.	27.0	810
5	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	1.4	512
6	The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. <i>Blood</i> , 2014, 123, 1637-1646.	1.4	394
7	MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. <i>Blood</i> , 2013, 121, 2051-2058.	1.4	368
8	International prognostic scoring system for Waldenström macroglobulinemia. <i>Blood</i> , 2009, 113, 4163-4170.	1.4	366
9	Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia. <i>Blood</i> , 2014, 123, 2791-2796.	1.4	337
10	A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degradator. <i>Cell Chemical Biology</i> , 2018, 25, 88-99.e6.	5.2	313
11	A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. <i>Blood</i> , 2013, 122, 1222-1232.	1.4	306
12	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. <i>British Journal of Haematology</i> , 2005, 128, 192-203.	2.5	305
13	Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 116-120.	2.2	304
14	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2018, 378, 2399-2410.	27.0	291
15	Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180. <i>Journal of Clinical Oncology</i> , 2009, 27, 3830-3835.	1.6	265
16	Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 474-481.	1.6	263
17	The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. <i>Blood</i> , 2020, 135, 1912-1915.	1.4	253
18	Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/V polymorphism. <i>Blood</i> , 2007, 110, 2561-2564.	1.4	244

#	ARTICLE	IF	CITATIONS
19	Response assessment in Waldenström macroglobulinaemia: update from the 4th International Workshop. British Journal of Haematology, 2013, 160, 171-176.	2.5	226
20	Diagnosis and Management of Waldenstrom's Macroglobulinemia. Journal of Clinical Oncology, 2005, 23, 1564-1577.	1.6	225
21	MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia. New England Journal of Medicine, 2015, 373, 584-586.	27.0	212
22	Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncology, The, 2017, 18, 241-250.	10.7	212
23	Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia. Journal of Clinical Oncology, 2009, 27, 120-126.	1.6	207
24	How I treat Waldenström macroglobulinemia. Blood, 2009, 114, 2375-2385.	1.4	206
25	Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. Journal of Immunotherapy, 2001, 24, 263-271.	2.4	188
26	Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248. Clinical Cancer Research, 2007, 13, 3320-3325.	7.0	186
27	Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene, 1997, 15, 837-843.	5.9	177
28	Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside Analogs. Journal of Clinical Oncology, 2009, 27, 250-255.	1.6	170
29	Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood, 2014, 124, 503-510.	1.4	168
30	How I treat Waldenström macroglobulinemia. Blood, 2015, 126, 721-732.	1.4	165
31	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood, 2016, 128, 1321-1328.	1.4	161
32	Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology, 2010, 28, 1422-1428.	1.6	150
33	CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. Journal of Immunotherapy, 2001, 24, 272-279.	2.4	144
34	Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. Journal of Clinical Oncology, 2018, 36, 2755-2761.	1.6	142
35	The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood, 2007, 110, 4417-4426.	1.4	141
36	Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood, 2009, 113, 3673-3678.	1.4	141

#	ARTICLE	IF	CITATIONS
37	Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2010, 85, 670-674.	4.1	138
38	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , 2014, 124, 1404-1411.	1.4	138
39	Thalidomide and rituximab in Waldenstrom macroglobulinemia. <i>Blood</i> , 2008, 112, 4452-4457.	1.4	135
40	Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H). <i>Clinical Cancer Research</i> , 2006, 12, 7174-7179.	7.0	133
41	Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1408-1414.	1.6	132
42	Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications. <i>Cancer Research</i> , 2004, 64, 2846-2852.	0.9	126
43	Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2009, 15, 355-360.	7.0	124
44	CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications. <i>Journal of Immunotherapy</i> , 2002, 25, 72-81.	2.4	123
45	Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 172, 735-744.	2.5	122
46	Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. <i>Blood</i> , 2017, 129, 2519-2525.	1.4	115
47	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. <i>Haematologica</i> , 2017, 102, 43-51.	3.5	112
48	Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. <i>British Journal of Haematology</i> , 2015, 169, 81-89.	2.5	110
49	Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 380-383.	1.4	107
50	Targeting NF- $\kappa$ B in Waldenstrom macroglobulinemia. <i>Blood</i> , 2008, 111, 5068-5077.	1.4	106
51	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. <i>Journal of Clinical Oncology</i> , 2020, 38, 1198-1208.	1.6	103
52	Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 133-135.	0.4	101
53	Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström macroglobulinemia. <i>Blood</i> , 2007, 109, 4964-4972.	1.4	100
54	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 565-575.	1.6	98

#	ARTICLE	IF	CITATIONS
55	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , 2020, 7, e827-e837.	4.6	96
56	<i>CXCR4</i> and <i>WHIM</i> -like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant <i>MYD88</i> <sup>L265P</sup> -directed survival signalling in Waldenström macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2015, 168, 701-707.	2.5	95
57	Treatment recommendations in Waldenström's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 121-126.	2.2	94
58	Hyperviscosity-Related Retinopathy in Waldenström Macroglobulinemia. <i>JAMA Ophthalmology</i> , 2006, 124, 1601.	2.4	94
59	HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. <i>Blood</i> , 2016, 127, 3237-3252.	1.4	93
60	Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenström Macroglobulinaemia who respond to a rituximab-containing regimen. <i>British Journal of Haematology</i> , 2011, 154, 357-362.	2.5	92
61	Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. <i>Blood</i> , 2014, 123, 3999-4000.	1.4	91
62	Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. <i>Blood</i> , 2016, 128, 827-838.	1.4	91
63	Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. <i>British Journal of Haematology</i> , 2016, 172, 709-715.	2.5	87
64	Uniform response criteria in Waldenström's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 127-131.	2.2	86
65	<i>MYD88</i> wild-type Waldenström Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. <i>British Journal of Haematology</i> , 2018, 180, 374-380.	2.5	83
66	Dual targeting of the proteasome regulates survival and homing in Waldenström macroglobulinemia. <i>Blood</i> , 2008, 111, 4752-4763.	1.4	79
67	The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. <i>Nature Medicine</i> , 2015, 21, 572-580.	30.7	79
68	Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 994-1001.	1.6	76
69	Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2008, 14, 1849-1858.	7.0	75
70	CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia. <i>Blood</i> , 2008, 112, 4683-4689.	1.4	74
71	<i>CXCR4</i> mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. <i>British Journal of Haematology</i> , 2019, 187, 356-363.	2.5	73
72	Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. <i>Blood Advances</i> , 2018, 2, 2937-2946.	5.2	72

#	ARTICLE	IF	CITATIONS
73	CD5, CD10, and CD23 Expression in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 246-249.	2.1	71
74	Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. <i>British Journal of Haematology</i> , 2019, 184, 558-569.	2.5	71
75	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. <i>Blood</i> , 2019, 133, 299-305.	1.4	69
76	Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2014, 89, 237-242.	4.1	68
77	Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. <i>British Journal of Haematology</i> , 2016, 175, 623-630.	2.5	68
78	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.	1.6	65
79	Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. <i>American Journal of Hematology</i> , 2007, 82, 83-84.	4.1	64
80	Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 62-66.	1.4	63
81	The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in wild-type and CXCRC4 <sup>hi</sup> WHIM <sup>hi</sup> mutated Waldenström macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2015, 170, 134-138.	2.5	63
82	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III INNOVATE Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 52-62.	1.6	62
83	Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. <i>Experimental Hematology</i> , 2007, 35, 1366-1375.	0.4	61
84	Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2011, 154, 223-228.	2.5	61
85	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 175, 77-86.	2.5	61
86	BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. <i>Blood</i> , 2018, 131, 2047-2059.	1.4	61
87	Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. <i>American Journal of Hematology</i> , 2018, 93, 511-517.	4.1	61
88	Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. <i>British Journal of Haematology</i> , 2017, 176, 728-742.	2.5	58
89	Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 177, 717-725.	2.5	58
90	Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2018, 24, 3247-3252.	7.0	57

#	ARTICLE	IF	CITATIONS
91	Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. <i>British Journal of Haematology</i> , 2017, 179, 339-341.	2.5	56
92	CHOP plus Rituximab Therapy in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 273-277.	2.1	55
93	IgA and IgG hypogammaglobulinemia in Waldenstrom's macroglobulinemia. <i>Haematologica</i> , 2010, 95, 470-475.	3.5	53
94	Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, 1032-1035.	4.1	53
95	CXCR4 in Waldenström's Macroglobulinemia: chances and challenges. <i>Leukemia</i> , 2021, 35, 333-345.	7.2	53
96	Venetoclax in Previously Treated Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 63-71.	1.6	53
97	Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, E312-3.	4.1	52
98	A new era for Waldenstrom macroglobulinemia: MYD88 L265P. <i>Blood</i> , 2013, 121, 4434-4436.	1.4	50
99	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. <i>Leukemia</i> , 2022, 36, 532-539.	7.2	50
100	Extramedullary Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2015, 90, 100-104.	4.1	47
101	Novel biologically based therapies for Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 309-312.	2.2	45
102	Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. <i>British Journal of Haematology</i> , 2003, 121, 592-596.	2.5	45
103	Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. <i>Haematologica</i> , 2018, 103, e307-e310.	3.5	45
104	How we manage Bing-Neel syndrome. <i>British Journal of Haematology</i> , 2019, 187, 277-285.	2.5	45
105	Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 1104-1107.	1.3	44
106	Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. <i>Blood</i> , 2011, 118, 276-281.	1.4	42
107	CD52 Is Expressed on Human Mast Cells and Is a Potential Therapeutic Target in Waldenström's Macroglobulinemia and Mast Cell Disorders. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 478-483.	1.4	41
108	Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2018, 181, 77-85.	2.5	41



#	ARTICLE	IF	CITATIONS
109	Balancing Risk Versus Benefit in the Treatment of Waldenström's Macroglobulinemia Patients with Nucleoside Analogue-Based Therapy. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 71-73.	1.4	40
110	Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1211-1219.	4.9	38
111	Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. <i>Oncologist</i> , 2016, 21, 1377-1386.	3.7	36
112	Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling. <i>Blood</i> , 2018, 131, 1720-1729.	1.4	36
113	Associated Malignancies in Patients with Waldenström's Macroglobulinemia and Their Kin. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 88-92.	0.4	35
114	Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. <i>Blood Advances</i> , 2020, 4, 3952-3959.	5.2	35
115	Rituximab intolerance in patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 174, 645-648.	2.5	34
116	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. <i>Blood Cancer Journal</i> , 2020, 10, 12.	6.2	34
117	Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations. <i>Seminars in Oncology</i> , 2003, 30, 248-252.	2.2	33
118	Hepcidin Is Produced by Lymphoplasmacytic Cells and Is Associated With Anemia in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 160-163.	0.4	33
119	Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database. <i>Cancer</i> , 2015, 121, 2230-2236.	4.1	33
120	TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2019, 184, 242-245.	2.5	33
121	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. <i>Blood</i> , 2021, 138, 1535-1539.	1.4	32
122	Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. <i>Leukemia and Lymphoma</i> , 2017, 58, 1002-1004.	1.3	31
123	Genetic Linkage of Fcγ <sub>3</sub> RIIa and Fcγ <sub>3</sub> RIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 286-290.	1.4	30
124	Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia. <i>Haematologica</i> , 2016, 101, e111-e115.	3.5	30
125	MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. <i>Haematologica</i> , 2018, 103, e408-e411.	3.5	30
126	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. <i>Blood</i> , 2018, 132, 2608-2612.	1.4	29



#	ARTICLE	IF	CITATIONS
127	CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. <i>Expert Review of Hematology</i> , 2019, 12, 873-881.	2.2	29
128	Ophthalmologic Techniques to Assess the Severity of Hyperviscosity Syndrome and the Effect of Plasmapheresis in Patients with Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 100-103.	1.4	28
129	Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 179-186.	2.5	28
130	Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM). <i>Blood</i> , 2014, 124, 1715-1715.	1.4	28
131	CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. <i>Blood Advances</i> , 2019, 3, 2800-2803.	5.2	27
132	Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. <i>Blood</i> , 2021, 138, 2002-2005.	1.4	27
133	Clinical Responses to Sildenafil in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 205-207.	2.1	26
134	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2226-2236.	7.0	26
135	Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 34-39.	2.0	25
136	Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. <i>Blood Advances</i> , 2019, 3, 3360-3374.	5.2	25
137	Familial Disease Predisposition Impacts Treatment Outcome in Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 433-437.	0.4	24
138	Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2019, 25, 369-377.	7.0	24
139	Management of Waldenström macroglobulinemia in 2020. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 372-379.	2.5	24
140	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. <i>Oncolmmunology</i> , 2017, 6, e1321184.	4.6	23
141	Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenström Macroglobulinemia (WMCTG 09-214). <i>Clinical Cancer Research</i> , 2017, 23, 2400-2404.	7.0	23
142	Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2020, 189, 1165-1170.	2.5	23
143	Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenström's Macroglobulinemia. <i>Blood</i> , 2015, 126, 1833-1833.	1.4	23
144	Report of the Third International Workshop on Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 215-216.	2.1	22

#	ARTICLE	IF	CITATIONS
145	Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 152-156.	0.4	22
146	Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. <i>Blood</i> , 2016, 127, 2598-2606.	1.4	22
147	CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. <i>Haematologica</i> , 2017, 102, e452-e455.	3.5	22
148	To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 176, 822-824.	2.5	22
149	Involvement of Ets Factor Spi-B and Id2 In Waldenström's Macroglobulinemia. <i>Blood</i> , 2010, 116, 129-129.	1.4	22
150	Defining Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 107-109.	2.2	21
151	The HMG-CoA inhibitor, simvastatin, triggers <i>in vitro</i> anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. <i>British Journal of Haematology</i> , 2008, 142, 775-785.	2.5	21
152	Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 945-970.	2.2	21
153	Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. <i>Blood</i> , 2009, 113, 626-634.	1.4	20
154	Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 110-117.	0.4	20
155	Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate™ Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5793-5800.	7.0	20
156	Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the INNOVATE™ Study. <i>Blood</i> , 2018, 132, 149-149.	1.4	20
157	Soluble CD27 Is a Faithful Marker of Disease Burden and Is Unaffected by the Rituximab-Induced IgM Flare, as Well as by Plasmapheresis, in Patients with Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 56-58.	1.4	19
158	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2015, 21, 2538-2545.	7.0	19
159	Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. <i>Clinical Cancer Research</i> , 2016, 22, 6099-6109.	7.0	19
160	MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2018, 180, 578-581.	2.5	19
161	What is new in the treatment of Waldenstrom macroglobulinemia?. <i>Leukemia</i> , 2019, 33, 2555-2562.	7.2	19
162	Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2019, 184, 1011-1014.	2.5	19

#	ARTICLE	IF	CITATIONS
163	Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 INNOVATETM Study. <i>Blood</i> , 2020, 136, 24-26.	1.4	19
164	The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM).. <i>Blood</i> , 2007, 110, 1516-1516.	1.4	19
165	Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. <i>British Journal of Haematology</i> , 2009, 145, 59-63.	2.5	17
166	Patients With Waldenström Macroglobulinemia Commonly Present With Iron Deficiency and Those With Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron Administration. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 241-243.	0.4	17
167	Biology, Prognosis, and Therapy of Waldenström Macroglobulinemia. <i>Cancer Treatment and Research</i> , 2015, 165, 177-195.	0.5	17
168	Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. <i>PLoS ONE</i> , 2018, 13, e0204589.	2.5	17
169	Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011, 118, 2951-2951.	1.4	17
170	Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor <i>SPIB</i> in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2014, 166, 677-689.	2.5	16
171	MYD88-independent growth and survival effects of Sp1 transactivation in Waldenström macroglobulinemia. <i>Blood</i> , 2014, 123, 2673-2681.	1.4	16
172	Waldenström macroglobulinemia: from biology to treatment. <i>Expert Review of Hematology</i> , 2014, 7, 157-168.	2.2	16
173	Initial Evaluation of the Patient with Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 811-820.	2.2	16
174	Genomic Landscape of Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 745-752.	2.2	16
175	Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 194, 730-733.	2.5	16
176	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. <i>Blood</i> , 2021, 138, 1966-1979.	1.4	16
177	Novel Agents in the Treatment of Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, S199-S206.	1.4	15
178	Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. <i>Clinical Cancer Research</i> , 2018, 24, 6408-6420.	7.0	15
179	Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia. <i>HemaSphere</i> , 2021, 5, e624.	2.7	15
180	Whole Genome Sequencing Reveals a Widely Expressed Mutation (MYD88 L265P) with Oncogenic Activity in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011, 118, 300-300.	1.4	15

#	ARTICLE	IF	CITATIONS
181	Bendamustine-Based Therapy Is Highly Active In Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2010, 116, 4700-4700.	1.4	15
182	microRNA Aberrations in Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 205-207.	0.4	14
183	Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 179, 106-115.	2.5	14
184	Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: A preliminary study. <i>Cancer Epidemiology</i> , 2012, 36, 294-297.	1.9	13
185	XIII. Waldenström's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features. <i>Hematological Oncology</i> , 2013, 31, 76-80.	1.7	13
186	Proteasome inhibitors in Waldenström macroglobulinemia. <i>Blood</i> , 2013, 122, 3243-3244.	1.4	13
187	Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. <i>American Journal of Hematology</i> , 2015, 90, E122-3.	4.1	13
188	Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 177, 808-813.	2.5	13
189	Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. <i>Blood Advances</i> , 2020, 4, 141-153.	5.2	13
190	B-Lymphocyte Stimulator Protein (BLYS) Is Expressed by Bone Marrow Mast and Lymphoplasmacytic Cells in Waldenstrom's Macroglobulinemia, and Provides Signaling for Growth, Survival and IgM Secretion.. <i>Blood</i> , 2004, 104, 3358-3358.	1.4	13
191	Low risk of <i>Pneumocystis jirovecii</i> pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib. <i>British Journal of Haematology</i> , 2019, 185, 788-790.	2.5	12
192	Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. <i>HemaSphere</i> , 2020, 4, e363.	2.7	12
193	CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. <i>American Journal of Hematology</i> , 2020, 95, E95-E98.	4.1	12
194	Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. <i>Blood Advances</i> , 2022, 6, 1015-1024.	5.2	12
195	CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. <i>Journal of Immunotherapy (1993-1997)</i> , 2001, 24, 272-279.	0.1	12
196	Advances in the Biology and Treatment of Waldenström's Macroglobulinemia: A Report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 10-15.	1.4	11
197	Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020, 4, e433.	2.7	11
198	Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. <i>Haematologica</i> , 2022, 107, 1163-1171.	3.5	11

#	ARTICLE	IF	CITATIONS
199	Serum Free Light Chain in Waldenstrom Macroglobulinemia.. Blood, 2006, 108, 2420-2420.	1.4	11
200	Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia. Blood, 2015, 126, 4004-4004.	1.4	11
201	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. Haematologica, 2021, 106, 2940-2946.	3.5	11
202	Interleukin-17 and TH17 Pathway Supports Waldenstrom's Macroglobulinemia Cell-Growth: Potential Therapeutic Implications. Blood, 2010, 116, 446-446.	1.4	11
203	IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood, 2021, 138, 1980-1985.	1.4	11
204	Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. Journal of Immunotherapy (1993-1997), 2001, 24, 263-271.	0.1	11
205	Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom's Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.. Blood, 2006, 108, 2765-2765.	1.4	10
206	Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. Blood Advances, 2022, 6, 2230-2235.	5.2	10
207	Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. Leukemia and Lymphoma, 2011, 52, 1777-1786.	1.3	9
208	Comparative Response Assessment by Serum Immunoglobulin M M-Protein and Total Serum Immunoglobulin M After Treatment of Patients With Waldenström Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 250-252.	0.4	9
209	Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e39-e40.	0.4	9
210	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 1388-1394.	1.3	9
211	Non-IgM Secreting Lymphoplasmacytic Lymphoma - Experience of a Reference Center for Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2886-2886.	1.4	9
212	A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTKCys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88. Blood, 2018, 132, 40-40.	1.4	9
213	Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. Blood, 2010, 116, 3952-3952.	1.4	9
214	Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.. Journal of Clinical Oncology, 2022, 40, 7566-7566.	1.6	9
215	Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology, 2021, 192, 542-550.	2.5	8
216	Cell-free DNA analysis for detection of MYD88 <sup>L265P</sup> and CXCR4 <sup>S338X</sup> mutations in Waldenström macroglobulinemia. American Journal of Hematology, 2021, 96, E250-E253.	4.1	8

#	ARTICLE	IF	CITATIONS
217	Comprehensive Molecular Characterization of Malignant and Microenvironmental Cells in Waldenstrom's Macroglobulinemia by Gene Expression Profiling.. Blood, 2007, 110, 3174-3174.	1.4	8
218	A Somatic Variant in MYD88 (L265P) Revealed by Whole Genome Sequencing Differentiates Lymphoplasmacytic Lymphoma From Marginal Zone Lymphomas. Blood, 2011, 118, 261-261.	1.4	8
219	Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia. Blood, 2016, 128, 2984-2984.	1.4	8
220	Preliminary Clinical Response Data from a Phase 1b Study of Mavoxifafor in Combination with Ibrutinib in Patients with Waldenstrom's Macroglobulinemia with MYD88 and CXCR4 Mutations. Blood, 2021, 138, 1362-1362.	1.4	8
221	Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 126-132.	3.0	7
222	Toward personalized treatment in Waldenstrom macroglobulinemia. Hematology American Society of Hematology Education Program, 2017, 2017, 365-370.	2.5	7
223	The race to stymie BTK: zanu zings. Blood, 2020, 136, 1997-1999.	1.4	7
224	Epigenetic targeting of Waldenstrom macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. Epigenomics, 2021, 13, 129-144.	2.1	7
225	Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenstrom's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNOVATETM Trial. Blood, 2020, 136, 38-39.	1.4	7
226	Phase II Study of CC-5013 (Revlimid) and Rituximab in Waldenstrom's Macroglobulinemia: Preliminary Safety and Efficacy Results.. Blood, 2005, 106, 2443-2443.	1.4	7
227	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. Blood, 2008, 112, 832-832.	1.4	7
228	Fcγ3 Receptor Predictive Genomic Testing and the Treatment of Indolent Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 321-322.	0.4	6
229	Novel approaches to targeting MYD88 in Waldenstrom macroglobulinemia. Expert Review of Hematology, 2017, 10, 739-744.	2.2	6
230	Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. American Journal of Hematology, 2020, 95, 372-378.	4.1	6
231	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenstrom Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 547-556.	0.4	6
232	Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study. Open Forum Infectious Diseases, 2022, 9, ofac104.	0.9	6
233	Epigenomics in Waldenstrom macroglobulinemia. Blood, 2020, 136, 527-529.	1.4	5
234	How to Sequence Therapies in Waldenstrom Macroglobulinemia. Current Treatment Options in Oncology, 2021, 22, 92.	3.0	5



#	ARTICLE	IF	CITATIONS
235	Establishment of a Waldenstrom's Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.. Blood, 2005, 106, 979-979.	1.4	5
236	IgA and IgG Hypogammaglobulinemia Is a Constitutive Feature in Most Waldenstrom's Macroglobulinemia Patients and May Be Related to Mutations Associated with Common Variable Immunodeficiency Disorder (CVID). Blood, 2008, 112, 3749-3749.	1.4	5
237	Whole-Genome Sequencing Results From 30 Patients with Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 434-434.	1.4	5
238	What should be the goal of therapy for Waldenstrom's macroglobulinemia patients? Complete response should be the goal of therapy. Blood Advances, 2017, 1, 2486-2490.	5.2	5
239	Future therapeutic options for patients with Waldenstrom's macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 206-215.	1.7	4
240	Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leukemia and Lymphoma, 2016, 57, 2699-2701.	1.3	4
241	Long survival in patients with Waldenstrom's macroglobulinaemia diagnosed at a young age. British Journal of Haematology, 2019, 185, 799-802.	2.5	4
242	Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia. Blood, 2018, 132, 1566-1566.	1.4	4
243	Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenstrom's Macroglobulinemia (WM).. Blood, 2006, 108, 2490-2490.	1.4	4
244	The Rituximab and IVIG Related IgM Flare In Waldenstrom's Macroglobulinemia Is Associated with Monocytic Activation of FcγRIIa Signaling, and Triggering of IL-6 Release by the PI3K/AKT and MAPK Pathways. Blood, 2010, 116, 2870-2870.	1.4	4
245	The importance of the genomic landscape in Waldenstrom's Macroglobulinemia for targeted therapeutical interventions. Oncotarget, 2017, 8, 35435-35444.	1.8	4
246	High frequency of central nervous system involvement in transformed Waldenstrom's macroglobulinemia. Blood Advances, 2022, 6, 3655-3658.	5.2	4
247	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Advances, 2022, 6, 3332-3338.	5.2	4
248	Waldenstrom's Macroglobulinemia/ Lymphoplasmacytic Lymphoma. , 2008, 142, 211-242.		4
249	Advances in the treatment of monoclonal gammopathies: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics: Targets and Therapy, 2008, 2, 419.	3.2	3
250	Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenstrom's macroglobulinemia. Blood Advances, 2020, 4, 4550-4553.	5.2	3
251	Clinical application of genomics in Waldenstrom's macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 1805-1815.	1.3	3
252	Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenstrom's Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response.. Blood, 2005, 106, 980-980.	1.4	3



#	ARTICLE	IF	CITATIONS
253	Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom's Macroglobulinemia.. Blood, 2006, 108, 2517-2517.	1.4	3
254	Treatment with a Bortezomib-Containing Regimen Is Associated with Better Therapeutic Outcomes in Patients with Waldenstrom's Macroglobulinemia Who Have Familial Disease Predisposition. Blood, 2011, 118, 1643-1643.	1.4	3
255	Incidence of Peripheral Neuropathy in Waldenstrom Macroglobulinemia Patients At Diagnosis,. Blood, 2011, 118, 3692-3692.	1.4	3
256	Polymorphisms in FcÎ³RIIIA Are Genetically Linked to FcÎ³RIIA and May Account for the Primary Predictive Role Ascribed to Polymorphisms in FcÎ³RIIIA-158 in Determining Rituximab Responses.. Blood, 2005, 106, 2433-2433.	1.4	3
257	Cleavage-Mediated Regulation of Myd88 Signaling by Inflammasome-Activated Caspase-1. Frontiers in Immunology, 2021, 12, 790258.	4.8	3
258	Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert Review of Anticancer Therapy, 2022, , .	2.4	3
259	Waldenström's Macroglobulinemia. Hematologic Malignancies, 2018, , 191-220.	0.2	2
260	The real world of Waldenström's macroglobulinaemia. Lancet Haematology,the, 2018, 5, e275-e276.	4.6	2
261	Reducing treatment toxicity in Waldenström macroglobulinemia. Expert Opinion on Drug Safety, 2021, 20, 1-8.	2.4	2
262	Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib. British Journal of Haematology, 2021, 195, 466-468.	2.5	2
263	Lymphoplasmacytic Cells and Mast Cells Are Targets for Imatinib Mesylate (Gleevec, Glivec) in Waldenstrom's Macroglobulinemia.. Blood, 2004, 104, 4929-4929.	1.4	2
264	The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom's Macroglobulinemia.. Blood, 2006, 108, 2496-2496.	1.4	2
265	Abnormalities in Lipoprotein Metabolism Provide Insight into Novel Therapeutic Approaches for Waldenstrom's Macroglobulinemia (WM).. Blood, 2006, 108, 4749-4749.	1.4	2
266	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood, 2007, 110, 4496-4496.	1.4	2
267	Microrna Expression Profile Identifies Distinct Clinically Relevant Sub-Groups in Multiple Myeloma: Novel Prognostic Markers and Potential Targets for Therapy. Blood, 2008, 112, 96-96.	1.4	2
268	Imatinib Mesylate (Gleevec®) Is Active in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-140.. Blood, 2006, 108, 2484-2484.	1.4	2
269	The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia.. Blood, 2006, 108, 2418-2418.	1.4	2
270	Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia.. Blood, 2006, 108, 2488-2488.	1.4	2

#	ARTICLE	IF	CITATIONS
271	Role of CCL5 and Interleukin-6 in the Biology of Waldenström Macroglobulinemia.. Blood, 2007, 110, 688-688.	1.4	2
272	Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom's Macroglobulinemia.. Blood, 2007, 110, 1383-1383.	1.4	2
273	MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenström's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors. Blood, 2010, 116, 2988-2988.	1.4	2
274	Aberrant Expression of Regulatory miRNAs and Transcripts for IRS-PI3K Growth and Survival Signaling In Waldenstrom's Macroglobulinemia. Blood, 2010, 116, 1912-1912.	1.4	2
275	Microarray Analysis of the Peripheral Monocytes From Waldenstrom's Macroglobulinemia Patients Reveals a Distinct Gene Expression Profile. Blood, 2010, 116, 2010-2010.	1.4	2
276	Epigenomics in Waldenstrom's macroglobulinaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 156-160.	1.7	1
277	Treatment Recommendations in Waldenström Macroglobulinemia. , 2017, , 367-370.		1
278	Genetic and Signaling Abnormalities in Waldenstrom's Macroglobulinemia. , 2017, , 53-65.		1
279	Comparing apples to oranges: A commentary on the <sc>M</sc>ayo study of <sc>MYD</sc>88 significance in <sc>W</sc>aldenstrom's macroglobulinemia.. American Journal of Hematology, 2018, 93, E69-E71.	4.1	1
280	Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, E201.	4.1	1
281	Genomic landscape of Waldenström's macroglobulinemia. HemaSphere, 2019, 3, 58-61.	2.7	1
282	Clinical Responses to Sildenafil in Waldenstrom's Macroglobulinemia.. Blood, 2004, 104, 4926-4926.	1.4	1
283	CHOP Plus Rituximab (CHOP-R) in Waldenström's Macroglobulinemia (WM).. Blood, 2004, 104, 4930-4930.	1.4	1
284	CD27-Mediated Apoptosis Is Dependent on Siva-Induced Caspase Activation in Human Multiple Myeloma.. Blood, 2005, 106, 3398-3398.	1.4	1
285	Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM).. Blood, 2007, 110, 1486-1486.	1.4	1
286	Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenström Macroglobulinemia: Preliminary Results.. Blood, 2007, 110, 4493-4493.	1.4	1
287	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. Blood, 2008, 112, 1011-1011.	1.4	1
288	Maintenance Rituximab Is Associated with Improved Progression Free and Overall Survival in Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 3750-3750.	1.4	1

#	ARTICLE	IF	CITATIONS
289	Gene Expression Profiling Distinguishes Waldenstrom's Macroglobulinemia Patients Presenting with Familial Disease, Advanced IPSS Prognostic Score, and Previous Treatment with Rituximab.. Blood, 2009, 114, 3930-3930.	1.4	1
290	The Anti-CD20 Monoclonal Antibody GA101 Displays More Robust Anti-Tumor Activity Versus Rituximab In Waldenstrom's Macroglobulinemia (WM). Blood, 2010, 116, 4904-4904.	1.4	1
291	Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 2705-2705.	1.4	1
292	Polymorphisms in the Hyaluronan Synthase 1 Gene May Be Predisposing Factors for Waldenstrom's Macroglobulinemia.. Blood, 2004, 104, 1363-1363.	1.4	1
293	Evaluation of CD52 Expression in Hematopoietic Neoplasms by Standard Immunohistochemistry: Implications for the Expanded Use of Alemtuzumab (CAMPATH-1H) in the Treatment of Hematological Malignancies.. Blood, 2005, 106, 3346-3346.	1.4	1
294	Sequence Analysis in the BLYS and APRIL Receptor TACI Reveals Novel Variants with a Potential Pathogenetic Role in Waldenstrom's Macroglobulinemia (WM).. Blood, 2005, 106, 991-991.	1.4	1
295	Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstrom's Macroglobulinemia, the Role of the ERK and PKC Pathways.. Blood, 2006, 108, 2416-2416.	1.4	1
296	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood, 2007, 110, 4494-4494.	1.4	1
297	Comprehensive Assessment of Cytokines and Chemokines In Patients with Waldenstrom's Macroglobulinemia Reveals a Distinct Profile with Pathobiological and Clinical Relevance. Blood, 2010, 116, 1911-1911.	1.4	1
298	Disruption of MYD88 Pathway Signaling Leads to Loss of Constitutive IRAK1, NF- $\kappa$ B and JAK/STAT Signaling and Induces Apoptosis of Cells Expressing the MYD88 L265P Mutation in Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 597-597.	1.4	1
299	Targeting Bruton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenstrom's Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment. Blood, 2011, 118, 883-883.	1.4	1
300	MYD88 L265P Promotes Survival of Waldenstrom's Macroglobulinemia Cells by Activation of Bruton's Tyrosine Kinase. Blood, 2012, 120, 897-897.	1.4	1
301	A pilot study on dasatinib in patients with Waldenstrom's macroglobulinemia progressing on ibrutinib. EJHaem, 2022, 3, 927-929.	1.0	1
302	WALDENSTROM-MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA. , 0, , 129-149.		0
303	Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 190-215.		0
304	Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 138-154.		0
305	12. Waldenstrom's macroglobulinemia. , 2016, , 229-244.		0
306	Signal Inhibitors in Waldenstrom's Macroglobulinemia. , 2017, , 327-334.		0

#	ARTICLE	IF	CITATIONS
307	Immunomodulatory Agents and Proteasome Inhibitors in Waldenstrom's Macroglobulinemia. , 2017, , 335-343.		0
308	Fitting mSMART Into the Current Clinical Management of Waldenstrom's Macroglobulinemia. JAMA Oncology, 2018, 4, 744.	7.1	0
309	Waldenstrom's Macroglobulinemia: Lessons Learned from Basic and Clinical Research. Hematology/Oncology Clinics of North America, 2018, 32, xiii-xiv.	2.2	0
310	Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma. , 2018, , 1419-1431.e5.		0
311	Waldenstrom's Macroglobulinemia. , 2018, , 617-638.		0
312	A Novel Murine Model for Human Waldenstrom's Macroglobulinemia.. Blood, 2004, 104, 3646-3646.	1.4	0
313	Induction of Multiple Myeloma-Specific Cytotoxic T Lymphocytes Using HLA-A2.1-Specific CD19 and CD20 Peptides.. Blood, 2004, 104, 2477-2477.	1.4	0
314	Mutator Genes UDG and AID Appear To Be Normal in Class-Switch Deficient and Clonally Homogeneous Waldenstrom's Macroglobulinemias Having Either Germline or Hypermutated Clonotypic IgH VDJ.. Blood, 2004, 104, 1359-1359.	1.4	0
315	Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) Using Nanoscale Protein Microarray Techniques.. Blood, 2005, 106, 504-504.	1.4	0
316	Hepatitis C Viral Infection Is Not Associated with Waldenstrom's Macroglobulinemia.. Blood, 2005, 106, 4693-4693.	1.4	0
317	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.. Blood, 2005, 106, 5150-5150.	1.4	0
318	Molecular Characterization of Clonotypic VDJ Sequences in Waldenstrom's Macroglobulinemia Suggests Independent Transformation Events in the Development of Biclinal B Cells.. Blood, 2006, 108, 4624-4624.	1.4	0
319	Targeting NF- $\kappa$ B by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM).. Blood, 2007, 110, 2512-2512.	1.4	0
320	Bone Marrow Niche Down-Regulates Mir-30 In Multiple Myeloma Cells to Promote Cancer Progression and Cancer Initiation by Targeting BCL9/Wnt Pathway.. Blood, 2010, 116, 1569-1569.	1.4	0
321	Involvement of Lipogenic Pathway In 5-Azacytidine-Induced Cytotoxicity In Waldenstrom's Macroglobulinemia. Blood, 2010, 116, 2991-2991.	1.4	0
322	Targeting Sp1 Transactivation In Waldenstrom's Macroglobulinemia: a Novel Therapeutic Option. Blood, 2010, 116, 120-120.	1.4	0
323	Associated Malignancies Among Patients and Kin with Waldenstrom's Macroglobulinemia. Blood, 2010, 116, 4159-4159.	1.4	0
324	Aberrant Expression of Oct-2, Spi-B, and Id2/Id1 Is Associated with Repression of Plasma Cell Differentiation in Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 86-86.	1.4	0

#	ARTICLE	IF	CITATIONS
325	The Role of Bortezomib-Containing Regimens in Improving Response in Patients with Waldenstrom Macroglobulinemia. Blood, 2011, 118, 2713-2713.	1.4	0
326	MicroRNA-21 and $\delta^{\sim}155$ Are Induced by a Widely Expressed Mutation in MyD88 (L265P) in Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 3957-3957.	1.4	0
327	Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenstrom Macroglobulinemia. Blood, 2012, 120, 3723-3723.	1.4	0
328	Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma. , 2013, , 83-109.		0
329	Waldenstrom's Macroglobulinemia. , 2014, , 303-329.		0
330	Bing-Neel Syndrome: A Rare Complication of Waldenstrom's Macroglobulinemia. Blood, 2014, 124, 5480-5480.	1.4	0
331	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. Blood, 2014, 124, 2070-2070.	1.4	0
332	Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies. Blood, 2018, 132, 263-263.	1.4	0
333	Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 207-227.		0